BIOSPAIN 2026

Engineered living materials (ELMs) are composed, either entirely or partly, of living cells. ELMs entirely composed of living cells are called biological ELMs and they self-assemble via a bottom-up process – e.g. synthetic morphogenesis for organoids’ production. ELMs only partly composed of living cells are called hybrid living materials (HLMs) and are built with a top-down process with integrated polymers or scaffolds. In both cases, the cellular components extract energy from the environment to form or assemble the material itself, and to adapt its morphology and function to environmental stimuli. This endows these materials with a combination of properties not present in any non-living material: self-regeneration, adaptation to environmental clues, longevity and environmental sustainability. By being alive, ELMs represent a fundamental change in materials’ production and performance, enabling new, better or similar functionalities, compared to traditional materials but with decreased costs and environmental impact. ELMs have the potential to transform virtually every modern endeavour from healthcare to infrastructures to transportation.

Representante de Cocoon?
Representante de Regemat3D?
Representante de BASF

Following the publication of the proposed Biotech Act I Regulation, the European Commission has launched a consultation process for the future Biotech Act II, which will focus on industrial policy and on building a broad, forward-looking biotechnology ecosystem.
In this session, organised by AseBio, we will examine the opportunities presented by Biotech Act II to advance biomanufacturing and biotechnology innovation in Europe, while also addressing the regulatory, financing, and scale-up challenges facing the sector.

Estado ponentes: 
Moderador: Ion Arocena, General Director of AseBio
Miguel Ángel Pavón, Directorate-General for Industrial Strategy and Small and Medium-sized Enterprises (SMEs), Ministry of Industry and Turism – mandada invitación

• Mrs Kristin Schreiber, Director Chemicals, Bioeconomy and Retail, DG GROW.F, European Commission – mandada invitación
• Joerg Lindemann - MD / Site Manager WACKER
• Ana Maria Bravo-Angel, Director of Public Affairs at IFF - mandada invitación

Europe has no shortage of ambitious strategies for biotechnology. The challenge now is implementation.
Delivering a competitive, resilient and sustainable European agri-food biotechnology ecosystem will require coordinated action across industry, startups, academia, investors, farmers, policymakers and innovation organisations. No single stakeholder can deliver this transformation alone.
This roundtable will build on the key insights and recommendations collected by the EU Agri-Food Biotech Alliance from representatives from across the entire value chain—including the European Commission, EFSA, industry leaders, startups, investors, research organisations, farmers, retailers and ecosystem partners—to identify the priorities and actions needed to accelerate biotechnology adoption in Europe.
The discussion will focus on how organisations can work together to reduce fragmentation, align around common priorities, launch collaborative initiatives and create greater impact through collective action. The session will conclude with a call for organisations across the value chain to join the effort and help shape a stronger, more connected European agri-food biotechnology ecosystem.

1. Conselleiro de Educación, Ciencia, Universidades y FP (Nota: Este seria nuestro Conselleiro, es donde esta integrada la Agencia Gallega de Innovación(GAIN))
Román Rodríguez González
Mails:
[email protected] (Conselleiro de Educación, Ciencia, Universidades y FP)
[email protected] (Jefe Gabinete Conselleiro)
[email protected] (Secretaria Conselleiro)
2. Conselleiro de Sanidad
Antonio Gómez Caamaño
Mails:
[email protected] (Conselleiro de Sanidad)
[email protected] (Jefa Gabinete Conselleiro)
[email protected] (Secretaria Conselleiro)

Regional biotechnology clusters and associations play a vital role in strengthening the biotechnology ecosystem by promoting collaboration among stakeholders, facilitating knowledge transfer, and accelerating the scientific and business development of the sector. Their work enhances the competitiveness of biotechnology companies while reinforcing the innovation and growth potential of their respective regions.

The aim of this session is to examine the role of biotechnology clusters in the development of the sector, explore how they collaborate with one another, and identify the key strengths and challenges across different regions, highlighting both shared priorities and the distinctive characteristics of each regional ecosystem. The discussion will also address the Biotech Act proposal to promote networks of biotechnology clusters as a means of strengthening competitiveness and fostering collaboration across the European biotechnology sector.

Propuesta de Ponentes: 

Moderador: Acesabio o bien AseBio y metemos a Acesabio como ponente?

• Idoia Muñoz, Directora del BHC
• Robert Fabregat, Director general de Biocat
• Jesús Agüero, Director Bioval
• Zara Pons, General Manager BIOIB
• Loli Pereiro, Manager Bioga

Imagine a crossroads where human health, animal welfare, and the environment meet — and a new generation of sentinels stands guard. This panel will convene those sentinels to tackle the urgent challenge of protecting vulnerable people and animals from disease driven by major antibiotic‑resistant threats, and to showcase the bleeding‑edge tools that spot and dissect multidrug‑resistant bacteria across clinical, food and environmental landscapes within a One Health framework. We’ll voyage through the knotted realities of vaccine development and market access, then move into the fast‑moving world of diagnostics: gene‑based LAMP assays that turn hours into minutes, electrochemical biosensors that read microbial whispers as electrical signals, nanomaterial‑amplified methods that reveal the faintest traces of pathogens, microfluidic “lab on a chip” platforms that miniaturize whole laboratories, and point‑of‑care systems built for real‑world decisions. The growing appreciation for vaccines—from immune surrogates of protection to fresh insights into host‑pathogen dynamics and sharper disease definitions—will be explored as a keystone for prevention. Recent breakthroughs already sound like science fiction: sub‑hour detection of key AMR genes, ultra‑low limits of detection in messy samples, and real‑time antimicrobial susceptibility testing that brings clinical and research timelines into alignment. These advances not only sharpen bedside decision making but also feed drug discovery with high‑resolution pathogen profiles that accelerate new antimicrobial development. The panel will bring together thought leaders in vaccines, diagnostics, microfluidics, biosensing, environmental microbiology, and pharmaceutical innovation to chart the next frontiers in AMR detection — and to imagine how those frontiers will reshape the hunt for tomorrow’s drugs.


Introduction – The One Health Challenge of MDR Bacteria (5 min)
Block 1 - From Immunity to Impact: Building Executable AMR Vaccines (15 min)
Block 2 – Genetic Detection of MDR Bacteria: LAMP and Other Rapid Molecular Techniques (15 min)
Block 3 – Electrochemical Biosensing: Fast, Sensitive Characterization of MDR Bacteria (15 min)
Block 4 – Point of Care Devices and Lab on a Chip Systems for Rapid AMR Decision-Making (15 min)
Block 5 – Connecting Diagnostics to Drug Development: The Feedback Loop (10 min)